Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Histopathology|January 4, 2008
Predictive markers in breast cancer--the futureD Faratian, J Bartlett
Histopathology|May 23, 2008
Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridizationA D Graham, D Faratian, F Rae, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 29, 2006
A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcomeD Faratian, A Stillie, R M C Busby-Earle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2009
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesS J Aitken, J S Thomas, S P Langdon, et al.
British Journal of Cancer|May 9, 2013
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistanceC Palmieri, O Gojis, B Rudraraju, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2007
Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancerO E Young, L Renshaw, E J Macaskill, et al.
British Journal of Cancer|May 3, 2012
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerA H Sims, A J M Zweemer, Y Nagumo, et al.
Oncogene|May 23, 2012
KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammalsS Moleirinho, N Chang, A H Sims, et al.
British Journal of Cancer|July 15, 2010
A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of SykE Katz, S Dubois-Marshall, A H Sims, et al.
Breast Cancer Research and Treatment|October 14, 2010
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative studyE J Macaskill, J M S Bartlett, V S Sabine, et al.
Pageof 1